BR112014015352A8 - tratamento de comprometimento cognitivo da síndrome de hunter por distribuição intratecal de iduronato-2-sulfatase - Google Patents

tratamento de comprometimento cognitivo da síndrome de hunter por distribuição intratecal de iduronato-2-sulfatase

Info

Publication number
BR112014015352A8
BR112014015352A8 BR112014015352A BR112014015352A BR112014015352A8 BR 112014015352 A8 BR112014015352 A8 BR 112014015352A8 BR 112014015352 A BR112014015352 A BR 112014015352A BR 112014015352 A BR112014015352 A BR 112014015352A BR 112014015352 A8 BR112014015352 A8 BR 112014015352A8
Authority
BR
Brazil
Prior art keywords
treatment
sulfatase
iduronate
intrathecal
cognitive impairment
Prior art date
Application number
BR112014015352A
Other languages
English (en)
Other versions
BR112014015352A2 (pt
Inventor
Barbier Ann
W Richard Charles Iii
Mccauley Thomas
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of BR112014015352A8 publication Critical patent/BR112014015352A8/pt
Publication of BR112014015352A2 publication Critical patent/BR112014015352A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

tratamento de comprometimento cognitivo da síndrome de hunter por distribuição intratecal de iduronato-2-sulfatase resumo a presente invenção fornece um método de tratamento de comprometimento cognitivo da síndrome de hunter. entre outras coisas, a presente invenção fornece um método que compreende uma etapa de administração intratecal, em um sujeito que necessita de tratamento, de uma enzima iduronato-2-sulfatase (i2s) recombinante em uma dose terapeuticamente eficaz e um intervalo de administração por um período de tratamento suficiente para melhorar, estabilizar ou reduzir o declínio de uma ou mais funções cognitivas, adaptativas, motoras e/ou executivas em relação a um controle.
BR112014015352A 2011-12-23 2012-12-21 tratamento de comprometimento cognitivo da síndrome de hunter por distribuição intratecal de iduronato-2-sulfatase BR112014015352A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161580027P 2011-12-23 2011-12-23
US201261590804P 2012-01-25 2012-01-25
US201261590797P 2012-01-25 2012-01-25
US201261609173P 2012-03-09 2012-03-09
US201261734365P 2012-12-06 2012-12-06
PCT/US2012/071495 WO2013096912A2 (en) 2011-12-23 2012-12-21 Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase

Publications (2)

Publication Number Publication Date
BR112014015352A8 true BR112014015352A8 (pt) 2017-06-13
BR112014015352A2 BR112014015352A2 (pt) 2017-06-13

Family

ID=48669720

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014015352A BR112014015352A2 (pt) 2011-12-23 2012-12-21 tratamento de comprometimento cognitivo da síndrome de hunter por distribuição intratecal de iduronato-2-sulfatase

Country Status (9)

Country Link
US (3) US9682129B2 (pt)
EP (1) EP2793933B1 (pt)
AU (1) AU2012358223B2 (pt)
BR (1) BR112014015352A2 (pt)
CA (1) CA2859988A1 (pt)
EA (1) EA201792099A1 (pt)
ES (1) ES2728447T3 (pt)
MX (2) MX367395B (pt)
WO (1) WO2013096912A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012358223B2 (en) 2011-12-23 2018-01-18 Takeda Pharmaceutical Company Limited Treatment of cognitive impairment of Hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
KR20170004814A (ko) 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
SG11201805598WA (en) 2015-12-30 2018-07-30 Green Cross Corp Methods and compositions for treating hunter syndrome
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
AU2003302724A1 (en) 2002-08-13 2004-07-09 Mcivor, Scott, R. Methods of using vectors to treat metabolic disorders
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
EP2588130B1 (en) 2010-06-25 2016-08-17 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
RU2012154576A (ru) 2010-06-25 2014-07-27 Шир Хьюман Дженетик Терапис, Инк. Способы и композиции для доставки к цнс гепаран-n-сульфатазы
NZ702800A (en) * 2010-06-25 2017-03-31 Shire Human Genetic Therapies Methods and compositions for cns delivery of heparan n-sulfatase
RU2660348C2 (ru) 2010-06-25 2018-07-05 Шир Хьюман Дженетик Терапис, Инк. Способы и композиции для доставки в цнс идуронат-2-сульфатазы
AU2012358223B2 (en) * 2011-12-23 2018-01-18 Takeda Pharmaceutical Company Limited Treatment of cognitive impairment of Hunter syndrome by intrathecal delivery of iduronate-2-sulfatase

Also Published As

Publication number Publication date
US9682129B2 (en) 2017-06-20
US11357832B2 (en) 2022-06-14
AU2012358223B2 (en) 2018-01-18
EP2793933B1 (en) 2019-04-17
AU2012358223A1 (en) 2014-07-03
EP2793933A4 (en) 2016-06-08
EP2793933A2 (en) 2014-10-29
WO2013096912A3 (en) 2015-06-18
ES2728447T3 (es) 2019-10-24
US20150328289A1 (en) 2015-11-19
MX2014007642A (es) 2015-03-19
EA201792099A1 (ru) 2018-05-31
US20180071371A1 (en) 2018-03-15
WO2013096912A2 (en) 2013-06-27
MX2019009846A (es) 2019-10-14
CA2859988A1 (en) 2013-06-27
BR112014015352A2 (pt) 2017-06-13
US20200376093A1 (en) 2020-12-03
MX367395B (es) 2019-08-20
US10568941B2 (en) 2020-02-25

Similar Documents

Publication Publication Date Title
EA201590880A1 (ru) Композиции и способы лечения протеинопатий
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
AU2012284088A8 (en) Heterocyclic compounds and uses thereof
GB2503852A (en) Compounds for the treatment of neuropsychiatric disorders
BR112015001847A8 (pt) Composições e tratamento para doenças e distúrbios nos olhos
EP2581092A4 (en) AGENT IMPROVING THE METABOLISM OF LIPIDS
GT201700246A (es) Métodos y kits para tratar la depresión
MX2017012426A (es) Composiciones y metodos para modular la expresion de tmprss6.
SG10201902074UA (en) Heterocyclic compounds and uses thereof
MX358640B (es) Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas.
BR112015005048A2 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
MX366175B (es) Composiciones fosfolipidicas terapeuticas concentradas.
BR112022007677A2 (pt) L-asparaginase recombinante
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
BR112015026238A2 (pt) tratamento de câncer com dihidropirazino-pirazinas
BR112014009785A8 (pt) método para tratar ou reduzir efp
BR112021020247A2 (pt) Composições e métodos para melhorar a saúde da pele e para o tratamento e prevenção de doenças, distúrbios e afecções associadas a micróbios patogênicos
BR112015003729A8 (pt) Composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
BR112015011213A2 (pt) Composto, composição farmacêutica, método de prevenção ou tratamento de um distúrbio ou doença de controle respiratório em um indivíduo, método de prevenção de desestabilização ou de estabilização do ritmo respiratório em um indivíduo, método de preparação de o,n-dimetil-n-[4-(n-propilamina)-6-(prop-2-inilamina)-[1,3,5]triazin-2-il]-hidroxilamina, e composição.
BR112014031866A2 (pt) Composição farmacêutica intramamária para utilização no tratamento ou prevenção da mastite em um mamífero não humano e composição farmacêutica de fosfomicina e de pelo menos um anti-microbiano
BR112014015352A2 (pt) tratamento de comprometimento cognitivo da síndrome de hunter por distribuição intratecal de iduronato-2-sulfatase
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112015017775A2 (pt) enzima cistationina beta-sintase para o tratamento de homocistinúria
BR112012030764A2 (pt) métodos para tratamento de distúrbios metotrexato-resistentes com 10-propargil-10-deazaanibopterin
BR112014024358A8 (pt) administração subcutânea de iduronato-2-sulfatase

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

B350 Update of information on the portal [chapter 15.35 patent gazette]